FDA - Spark Newswire

2 minute read

FDA
News

Nemaura Medical Announces Presentation On Its Licensed Why WAIT Program During American Diabetes Association 81st Annual Scientific Sessions

Today, 5:56 PM

Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting

NMRD

4 minute read

SELLAS Reports Updated Clinical Data From Phase 1/2 Study Of Galinpepimut-S Combined With Keytruda Showing 100% Of Patients Alive And 45.5 Percent Continuing Investigational Therapy As Of The Latest Follow-Up

By Bill Haddad

Today, 5:56 PM

Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS Induced WT1-Specific Immune

SLS

2 minute read

Allogene Therapeutics Granted FDA Fast Track Designation For ALLO-605, A TurboCAR T Cell Therapy, For The Treatment Of Relapsed/Refractory Multiple Myeloma

By Bill Haddad

Today, 5:56 PM

Phase 1 IGNITE Dose Escalation Trial of ALLO-605 Initiated in Q2 2021 ALLO-605 is the Third Prong of the Company's Clinical Strategy to Target BCMA for the Treatment of Multiple

ALLO

4 minute read

Ocuphire Announces VEGA-1 Phase 2 Trial In Presbyopia Meets Primary And Secondary Endpoints

By Bill Haddad

Today, 5:56 PM

Met primary endpoint with statistical significance at 1 hour with 61% of subjects treated with Nyxol® plus low-dose pilocarpine (LDP) gaining ≥ 15 letters (3 lines) in near

OCUP

2 minute read

Lyra Therapeutics Announces Topline Results Of Pharmacokinetic Study Of LYR-210 In Patients With Chronic Rhinosinusitis; Says Results Support 505(b)(2) NDA Pathway For LYR-210

By Bill Haddad

Today, 5:56 PM

-- Results Support 505(b)(2) NDA Pathway for LYR-210 -- First U.S. Study of LYR-210 Enrolled Rapidly WATERTOWN, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA), a

LYRA

1 minute read

Compugen Doses First Patient In COM701/Opdivo Phase 1b Cohort Expansion Study

By Bill Haddad

Today, 5:56 PM

Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in the combination expansion cohort

CGEN

3 minute read

Atea Pharmaceuticals Announces Interim Results From Phase 2 Study Of AT-527 Showing ‘Rapid and Sustained Antiviral Activity Against SARS-CoV-2 in Patients with COVID-19 in the Hospitalized Setting’

By Bill Haddad

Today, 5:56 PM

Phase 2 Interim Virology Results Indicate Rapid and Sustained Antiviral Activity Against SARS-CoV-2 in Patients with COVID-19 in the Hospitalized Setting AT-527 is Being Studied in Multiple Clinical Studies, Including

AVIR

4 minute read

Sinovac Highlights Publication Of Phase I/II COVID-19 Study In The Lancet Infectious Diseases

By Bill Haddad

Today, 5:56 PM

- CoronaVac® is safe among the pediatric group aged 3 to 17 years old - CoronaVac can induce strong antibody responses in this pediatric group Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the

SVA

1 minute read

Altimmune Stock Tanks On Double Bad News From COVID-19 Program

By Vandana Singh

Today, 5:56 PM

Altimmune Inc (NASDAQ:ALT) revealed it would hit the pause button on its immunomodulatory candidate for COVID-19, dubbed T-COVID, citing enrollment challenges.…

ALT

3 minute read

Athersys Highlights Data Published In Scientific Reports Journal Involving MultiStem

By Bill Haddad

Today, 5:56 PM

Athersys, Inc. (NASDAQ:ATHX) announced today that data accumulated from several years of preclinical research was published in the peer-reviewed journal Scientific Reports. The publication describes the findings

ATHX